Clinical Data Finds Strong Association between HDL Particles and Coronary Heart Disease

Study Published in JACC Suggests HDL Particles May Be a More Accurate Indicator of Cardiovascular Health Than HDL Cholesterol

RALEIGH, N.C.--(BUSINESS WIRE)--Jul 12, 2012 - LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced publication of the findings of a clinical study in the current issue of the Journal of the American College of Cardiology indicating that high density lipoprotein (HDL) particle number has a stronger, more independent association with coronary heart disease and carotid atherosclerosis than HDL cholesterol (HDL-C).

Clinicians have historically used levels of HDL cholesterol, referred to as “good cholesterol,” to help assess a patient's risk for cardiovascular disease (CVD). However, recent studies have called into question the consistency of the relationship between HDL-C levels and CVD risk, and in particular whether high HDL-C is always protective. This new study suggests the problem may be that because HDL-C levels are linked to many other markers of CVD risk, it is difficult to determine the importance of HDL-C as an independent risk factor. An alternative biomarker of HDL-related risk is HDL particle number (HDL-P), which the study found to be more strongly associated and more independent of other risk markers with atherosclerosis and coronary heart disease (CHD) events.

“This study found that baseline levels of HDL-C and HDL-P were both inversely associated with CHD events and carotid atherosclerosis in this study population. However, HDL-C risk associations were partially explained by other risk factors, such as low density lipoprotein particle number (LDL-P), triglycerides, and HDL-P,” said Robert Honigberg, M.D., Chief Medical Officer and Vice President, Medical Affairs of LipoScience. “These results further validate the need to look at alternate measures beyond traditional cholesterol values in the risk assessment and management of heart disease.”

Researchers analyzed blood samples obtained at study onset from 5,598 middle-aged men and women free of cardiovascular disease who participated in the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective observational study initiated and overseen by the National Heart, Lung and Blood Institute. Participants were followed for a mean of six years for incident CHD events – including angina, heart attack, and coronary heart disease death.

"Negative results from recently published studies looking at the effects of treatments on HDL cholesterol levels have led many clinicians to question the benefit of HDL-raising therapy,” said Samia Mora, M.D., Assistant Professor of Medicine at Harvard Medical School, and cardiologist at the Brigham and Women's Hospital in Boston and senior investigator of this study. “In the MESA study, we found that increased numbers of HDL particles had stronger cardio-protection than HDL cholesterol. We need more research extending beyond HDL cholesterol measurement to sort out the different functional properties of HDL, since HDL cholesterol is only one part of the HDL story."

HDL particle levels were measured using LipoScience's NMR LipoProfile® test, which detects the concentration of low density and high density lipoprotein particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for cardiovascular disease. To date, over 7 million NMR LipoProfile tests have been ordered to aid in the management of patients' heart heath.

About LipoScience, Inc.
LipoScience, Inc. is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary technology platform based on nuclear magnetic resonance (NMR) technology. Our first diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 7 million NMR LipoProfile tests have been ordered. For further information on the Company, please visit www.liposcience.com and www.theparticletest.com.

Contact: Schwartz MSL
Benjamin Navon/Kristen Perry, 781-684-0770
liposcience@schwartzmsl.com
or
LipoScience, Inc.
Tori Hall, 919-256-1046
tori.hall@liposcience.com

 

Posted: July 2012

View comments

Hide
(web3)